(CRNX) Crinetics Pharmaceuticals - Ratings and Ratios
Paltusotine, Atumelnant, CRN09682, PTH Antagonist, Radionetics
CRNX EPS (Earnings per Share)
CRNX Revenue
Description: CRNX Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical-stage biotech company focused on developing novel therapeutics for rare endocrine diseases and endocrine-related tumors, with a pipeline of promising candidates including Paltusotine, Atumelnant, and CRN09682.
The companys lead product, Paltusotine, is a nonpeptide somatostatin receptor type 2 agonist in Phase 3 trials for acromegaly and carcinoid syndrome associated with neuroendocrine tumors, showing potential for a significant market impact. Additionally, Atumelnant has completed Phase 1 studies for treating diseases caused by excess adrenocorticotrophic hormone (ACTH).
From a Key Performance Indicator (KPI) perspective, Crinetics Pharmaceuticals has a market capitalization of approximately $2.9 billion, indicating a substantial investor interest. The absence of a Price-to-Earnings (P/E) ratio is expected for a company in the clinical-stage with no current earnings, but this also signifies potential for future growth as the pipeline progresses. The Return on Equity (RoE) of -30.95% highlights the companys current investment in research and development, a common trait among biotech firms focused on bringing new therapies to market.
The companys diversified pipeline, including antagonists of the parathyroid hormone (PTH) receptor, thyroid-stimulating hormone receptor antagonists, and nonpeptide drug conjugates, positions it for potential long-term success across multiple therapeutic areas. Strategic partnerships, such as the agreement with Sanwa Kagaku Kenkyusho Co., Ltd for Paltusotine in Japan, further enhance its prospects.
To gauge the companys progress and potential, key metrics to monitor include the advancement of Paltusotine through Phase 3 trials, the initiation and results of further clinical trials for other pipeline candidates, and any updates on its partnerships and commercialization efforts.
CRNX Stock Overview
| Market Cap in USD | 3,263m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-07-18 |
CRNX Stock Ratings
| Growth Rating | 10.7% |
| Fundamental | 21.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -44.3% |
| Analyst Rating | 4.59 of 5 |
CRNX Dividends
Currently no dividends paidCRNX Growth Ratios
| Growth Correlation 3m | 20.9% |
| Growth Correlation 12m | -84.5% |
| Growth Correlation 5y | 78.6% |
| CAGR 5y | 18.38% |
| CAGR/Max DD 3y | 0.32 |
| CAGR/Mean DD 3y | 1.64 |
| Sharpe Ratio 12m | 0.39 |
| Alpha | -66.50 |
| Beta | 1.741 |
| Volatility | 52.24% |
| Current Volume | 1151.9k |
| Average Volume 20d | 1151.9k |
| Stop Loss | 31.9 (-6.2%) |
| Signal | 0.38 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-369.8m TTM) > 0 and > 6% of Revenue (6% = 83.5k TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA 0.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 82.5k% (prev 59.2k%; Δ 23.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.23 (>3.0%) and CFO -301.8m > Net Income -369.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 17.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (93.8m) change vs 12m ago 18.71% (target <= -2.0% for YES) |
| Gross Margin -112.4% (prev -27.22%; Δ -85.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.13% (prev 0.15%; Δ -0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 10.76
| (A) 0.89 = (Total Current Assets 1.22b - Total Current Liabilities 68.4m) / Total Assets 1.29b |
| (B) -0.90 = Retained Earnings (Balance) -1.16b / Total Assets 1.29b |
| (C) -0.38 = EBIT TTM -424.0m / Avg Total Assets 1.11b |
| (D) 9.93 = Book Value of Equity 1.17b / Total Liabilities 118.0m |
| Total Rating: 10.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 21.31
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -10.82% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -0.13 = -2.50 |
| 6. ROIC - WACC -49.27% = -12.50 |
| 7. RoE -32.28% = -2.50 |
| 8. Rev. Trend -34.39% = -1.72 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -78.85% = -1.97 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CRNX shares?
Over the past week, the price has changed by -4.52%, over one month by +19.38%, over three months by +5.69% and over the past year by -33.63%.
Is Crinetics Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRNX is around 33.02 USD . This means that CRNX is currently overvalued and has a potential downside of -2.88%.
Is CRNX a buy, sell or hold?
- Strong Buy: 11
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CRNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 69.4 | 104.1% |
| Analysts Target Price | 69.4 | 104.1% |
| ValueRay Target Price | 36 | 5.8% |
Last update: 2025-09-05 04:38
CRNX Fundamental Data Overview
CCE Cash And Equivalents = 1.20b USD (Cash And Short Term Investments, last quarter)
P/S = 2344.2517
P/B = 2.6769
Beta = 0.332
Revenue TTM = 1.39m USD
EBIT TTM = -424.0m USD
EBITDA TTM = -420.6m USD
Long Term Debt = 49.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 6.61m USD (from shortTermDebt, last quarter)
Debt = 56.3m USD (Calculated: Short Term 6.61m + Long Term 49.7m)
Net Debt = -3.79m USD (from netDebt column, last quarter)
Enterprise Value = 2.12b USD (3.26b + Debt 56.3m - CCE 1.20b)
Interest Coverage Ratio = unknown (Ebit TTM -424.0m / Interest Expense TTM 0.0)
FCF Yield = -10.82% (FCF TTM -229.8m / Enterprise Value 2.12b)
FCF Margin = -16.5k% (FCF TTM -229.8m / Revenue TTM 1.39m)
Net Margin = -26.6k% (Net Income TTM -369.8m / Revenue TTM 1.39m)
Gross Margin = -112.4% ((Revenue TTM 1.39m - Cost of Revenue TTM 2.96m) / Revenue TTM)
Tobins Q-Ratio = 1.81 (Enterprise Value 2.12b / Book Value Of Equity 1.17b)
Interest Expense / Debt = 3.52% (Interest Expense 1.98m / Debt 56.3m)
Taxrate = 21.0% (US default)
NOPAT = -424.0m (EBIT -424.0m, no tax applied on loss)
Current Ratio = 17.80 (Total Current Assets 1.22b / Total Current Liabilities 68.4m)
Debt / Equity = 0.05 (Debt 56.3m / last Quarter total Stockholder Equity 1.17b)
Debt / EBITDA = -0.13 (Net Debt -3.79m / EBITDA -420.6m)
Debt / FCF = -0.24 (Debt 56.3m / FCF TTM -229.8m)
Total Stockholder Equity = 1.15b (last 4 quarters mean)
RoA = -28.68% (Net Income -369.8m, Total Assets 1.29b )
RoE = -32.28% (Net Income TTM -369.8m / Total Stockholder Equity 1.15b)
RoCE = -35.47% (Ebit -424.0m / (Equity 1.15b + L.T.Debt 49.7m))
RoIC = -37.01% (NOPAT -424.0m / Invested Capital 1.15b)
WACC = 12.27% (E(3.26b)/V(3.32b) * Re(12.43%)) + (D(56.3m)/V(3.32b) * Rd(3.52%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 5.19%
Discount Rate = 12.43% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -229.8m)
Revenue Correlation: -34.39 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: 80.02
EPS Correlation: -78.85 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 3.30
Additional Sources for CRNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle